Thank you, eom7. I didn't realize that the tocilizumab trial was conducted in Spain and incorporated "...a retrospective cohort study..." This is just like the smaller Mayo Clinic study of lenz, conducted in the US.
The 14.7% reduction in mortality equated to a Relative Risk Reduction of 46.7%. That effect of tocilizumab was added to that of steroids which were administered "...to non-intubated patients with COVID-19 during the first 48 h of presenting with respiratory failure despite oxygen therapy."
I think this could be key as to why the tocilizumab trial included both ventilated as well as non-ventilated patients, which I think I heard Dale say that it did.
I think the "age adjusted" mortality reduction achieved with leronlimab in patients <65 years old may be better than that. But I don't think our management team agrees (or that age adjusted mITT was announced after Dale's video conference).
Regardless, the projected results of both of those drugs require randomized controlled studies to be confirmed. Durrant's successful validation experience, and Chappell's bold reflexive course changes, have brought us to the finish line with a trial that likely has checked all the boxes for trial approval.
News 
Market Data 
Discover 
